NTRBW | Nutriband Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5300 - 1.6400
52 Week Range	0.3530 - 5.25
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	594
Average Volume	12,550
Shares Outstanding	37,580,929
Market Cap	57,498,821
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-01

Valuation
Profitability
Growth
Health
P/E Ratio	-3.03
Forward P/E Ratio	N/A
EPS	-0.51
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	NTRBW

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.

NTRBW's peers: ARTL, KTTA, NTRB, HCWB, NRXPW, BFRIW, ZIVO

*Chart delayed

Analyzing fundamentals for NTRBW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong. For more detailed analysis please see NTRBW Fundamentals page.

Watching at NTRBW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NTRBW Technicals page.